BOSTON, July 7, 2016 /PRNewswire-USNewswire/ -- Shares in Juno Therapeutics Inc. ("Juno" or the "Company") (NASDAQ: JUNO) have plunged approximately 28%, after the Company disclosed that two patients died "last week" and a third died in May in clinical trials of its immuno-oncology therapeutic JCAR15. All three patients died of a cerebral edema after receiving a drug called fludarabine as part of the pre-conditioning regimen. A number of previously published clinical articles have identified a possible link between fludarabine and neurotoxicity.
Despite this literature and despite learning of the first patient death in May, Juno does not appear to have previously disclosed the first patient death to investors. Moreover, on June 30, 2016—prior to the disclosure of these deaths—Juno's CEO Bishop Hans Edgar sold over $4.4 million worth of the Company's stock.
Block & Leviton LLP is investigating the Company and certain of its officers to determine whether investors may be able to bring claims to recover their losses under the federal securities laws.
If you purchased Juno stock between June 4, 2016 and July 7, 2016 and have questions about your legal rights, or if you have information relevant to this investigation, please contact attorney Joel Fleming of Block & Leviton LLP at (617) 398-5600 or at Joel@blockesq.com. Confidentiality for any whistleblowers or other persons with information relevant to the investigation is assured.
Block & Leviton is a Boston-based law firm representing investors for violations of securities laws as well as whistleblowing employees who provide information about their employers' violations of law. The firm's lawyers have collectively been prosecuting securities cases on behalf of investors for over 70 years.
This notice may constitute attorney advertising.
BLOCK & LEVITON LLP
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/block--leviton-investigates-juno-therapeutics-after-announcement-of-previously-unreported-patient-deaths-in-clinical-trial-300295762.html
SOURCE Block & Leviton LLP